Skip to main content
DNA Labs India

Hemophilia A Carrier Detection Test

DNA Labs India | ISO 9001:2015 Certified

Hemophilia A Carrier Detection Test

Short Name: Hemophilia A Carrier Test

Also known as: Factor VIII Carrier Detection Test, Hemophilia A Carrier Screening, Haemophilia A Carrier Test, Factor VIII to vWF Ratio Test

Hemophilia A Carrier Detection Test test available at DNA Labs India for ₹0. Uses Electromechanical Clot Detection, EIA (Enzyme Immunoassay) on Whole Blood (Platelet-Poor Plasma) samples. Results in Reports available the next working day after sample receipt. Samples collected on the 1st and 3rd Monday by 11:00 AM; reports delivered the following day.. Free home collection in 300+ cities across India.

Blood TestFemale🏠 Home Collection

✍️ Written By

🩺 Medically Reviewed By

Dr Pasupathy Arumugam

Dr Pasupathy Arumugam

Consultant Pathologist · Reg: 21521

Last reviewed: September 7, 2026

Overview

The primary purpose of the Hemophilia A Carrier Detection Test is to determine whether a woman carries the defective gene responsible for Hemophilia A. By measuring the ratio of Factor VIII clotting activity to von Willebrand Factor (vWF) antigen concentration, the test can reliably distinguish carriers from non-carriers. A ratio below 1.0 is indicative of carrier status, as carriers typically exhibit reduced Factor VIII activity relative to their vWF antigen level. This information is vital for genetic counselling, reproductive planning, and ensuring appropriate medical surveillance for children who may inherit the disorder.

Test Code
701
ICD Code
D66
Sample Type
Whole Blood (Platelet-Poor Plasma)
Result Time
Reports available the next working day after sample receipt. Samples collected on the 1st and 3rd Monday by 11:00 AM; reports delivered the following day.
Fasting Required
Yes
Method
Electromechanical Clot Detection, EIA (Enzyme Immunoassay)
Step 1

Sample Collection

Overnight fasting (8–12 hours) is preferred. Heparin should be discontinued for 1 day and oral anticoagulants for 7 days prior to sampling, with prior consent from the treating physician. A duly filled Coagulation Requisition Form (Form 15) is mandatory. Avoid strenuous exercise and alcohol for 24 hours before the test.

Method: Venipuncture

Step 2

Laboratory Analysis

A trained phlebotomist will collect 3 mL of whole blood via venipuncture into a Blue Top (Sodium Citrate) tube. The tube must be mixed thoroughly by gentle inversion (8–10 times) immediately after collection to prevent clotting.

Step 3

Report Delivery

Apply pressure to the puncture site for 3–5 minutes. Minor bruising is normal. The sample must be transported to the laboratory within 4 hours of collection. If this is not possible, platelet-poor plasma (PPP) must be prepared within 1 hour and frozen immediately.

Timeline: Reports available the next working day after sample receipt. Samples collected on the 1st and 3rd Monday by 11:00 AM; reports delivered the following day.

Patient Instructions

1
Before the Test:Overnight fasting (8–12 hours) is preferred. Discontinue Heparin for 1 day and oral anticoagulants for 7 days prior to sampling with treating physician's consent. Bring a duly filled Coagulation Requisition Form (Form 15). Avoid strenuous physical activity and alcohol for 24 hours before the test.
2
During the Test:A healthcare professional will draw approximately 3 mL of blood from a vein in your arm using a needle. The blood is collected into a Sodium Citrate (Blue Top) tube and gently mixed by inversion. The procedure typically takes less than 10 minutes. Mild discomfort or a small bruise at the puncture site may occur.
3
After the Test:Apply firm pressure to the puncture site for 3–5 minutes. You may resume normal activities immediately. If you discontinued any anticoagulant medications, consult your doctor about when to resume them. Reports are typically available the next day via online portal, email, or WhatsApp.

About This Test

Who Should Get This Test

The primary purpose of the Hemophilia A Carrier Detection Test is to determine whether a woman carries the defective gene responsible for Hemophilia A. By measuring the ratio of Factor VIII clotting activity to von Willebrand Factor (vWF) antigen concentration, the test can reliably distinguish carriers from non-carriers. A ratio below 1.0 is indicative of carrier status, as carriers typically exhibit reduced Factor VIII activity relative to their vWF antigen level. This information is vital for genetic counselling, reproductive planning, and ensuring appropriate medical surveillance for children who may inherit the disorder.

How to Prepare

  • Collect 3 mL whole blood in 1 Blue Top (Sodium Citrate) tube.
  • Mix thoroughly by gentle inversion immediately after collection.
  • Transport to the laboratory within 4 hours of collection.
  • If transport within 4 hours is not possible, prepare PPP within 1 hour as follows: Centrifuge at 3600 rpm for 15 minutes, transfer supernatant to a clean plastic tube, centrifuge again at 3600 rpm for 15 minutes, and transfer final supernatant (PPP) to a labelled, clean plastic screw-capped vial.
  • FREEZE PPP IMMEDIATELY. Ship frozen. DO NOT THAW.
  • Duly filled Coagulation Requisition Form (Form 15) must accompany the sample.

Doctor's Notes

Reviewed by — MBBS, MD (Pathology) · Reg. No. 21521

"As a clinical geneticist, I strongly recommend Hemophilia A carrier testing for women with a known family history of the disorder, particularly when planning a family. The Factor VIII-to-vWF antigen ratio is a well-validated biochemical marker that identifies over 95% of carriers. Early detection enables informed reproductive decisions, facilitates appropriate genetic counselling, and ensures that at-risk children receive timely medical intervention. Carrier testing should ideally be performed before conception or during early pregnancy planning so that all available reproductive options can be discussed comprehensively."

Last medically reviewed: September 7, 2026

Test Parameters & Specifications

Sample TypeWhole Blood (Platelet-Poor Plasma)
Sample Volume3 mL
ContainerBlue Top (Sodium Citrate) tube
Collection MethodVenipuncture

Sample Stability

Room Temperature
Refrigerated (2–8°C)
Frozen (≤ -20°C) – PPP only
Sample Rejection Criteria:
  • Clotted or haemolysed sample
  • Sample collected in incorrect tube (not Sodium Citrate Blue Top)
  • Sample received without Coagulation Requisition Form (Form 15)
  • Thawed frozen PPP sample
  • Sample exceeding stability time limits
  • Insufficient sample volume (< 3 mL)

Understanding Your Results

The Hemophilia A Carrier Detection Test is interpreted by evaluating the ratio of Factor VIII clotting activity to von Willebrand Factor (vWF) antigen concentration. In normal females, Factor VIII activity and vWF antigen levels are roughly proportional, yielding a ratio close to or greater than 1.0. In carriers, Factor VIII activity is disproportionately reduced relative to vWF antigen due to random X-chromosome inactivation (lyonisation), producing a ratio below the established threshold. Results should always be interpreted in the context of family history, clinical presentation, and, when indicated, confirmatory molecular genetic testing.
📊

Factor VIII/vWF Ratio ≥ 0.9

Normal – Not consistent with carrier status. Factor VIII and vWF levels are proportionally normal.

Status: Negative

📊

Factor VIII/vWF Ratio < 0.9

Consistent with Hemophilia A carrier status. Biochemically identifies 95–99% of carriers. Recommend confirmatory genetic testing (F8 gene mutation analysis) and genetic counselling.

Status: Positive

📊

Factor VIII/vWF Ratio 0.9–1.0 (Borderline)

Indeterminate. Correlation with family history is essential. Repeat testing or confirmatory molecular genetic testing is recommended.

Status: Borderline

📊

Low Factor VIII Activity with Normal vWF Antigen

Suggestive of carrier status or mild Hemophilia A (in males). Clinical correlation and genetic testing advised.

Status: Further evaluation needed

⚠️ When to Consult a Doctor:

Consult a haematologist or clinical geneticist if your Factor VIII/vWF ratio is less than 0.9, if you have a family history of Hemophilia A and are planning a family, if your results fall in the borderline range (0.9–1.0), or if you experience symptoms of a bleeding disorder such as unexplained bruising, prolonged bleeding, or heavy menstrual periods.

Limitations

  • ⚠Biochemical carrier detection may not identify all carriers; approximately 1–5% of confirmed carriers have a normal Factor VIII/vWF ratio.
  • ⚠Molecular genetic testing (F8 gene mutation analysis) is considered the gold standard for definitive carrier confirmation.
  • ⚠Results may be unreliable during pregnancy, acute illness, or while the patient is on anticoagulant therapy.
  • ⚠This test does not predict the severity of disease in potential offspring.
  • ⚠Borderline ratios (0.9–1.0) require correlation with family history and may need genetic confirmation.

Risks & Considerations

  • ●Minor bruising or discomfort at the venipuncture site
  • ●Slight risk of infection at the puncture site (rare)
  • ●Lightheadedness or dizziness during blood draw (uncommon)
  • ●Patients on anticoagulants face a slightly higher risk of prolonged bleeding at the puncture site

Interfering Factors

  • ●Heparin therapy (discontinue for 1 day prior to sampling with physician consent)
  • ●Oral anticoagulant therapy (discontinue for 7 days prior to sampling with physician consent)
  • ●Acute-phase reactions which may elevate vWF antigen levels
  • ●Pregnancy, which increases both Factor VIII and vWF levels and may affect the ratio
  • ●Stress, exercise, or inflammation at the time of blood draw
  • ●Oestrogen-containing oral contraceptives which may alter Factor VIII and vWF levels
  • ●Improper sample handling, delayed processing, or thawed frozen samples

Compare With Similar Tests

TestHemophilia A Carrier Detection TestFactor VIII Activity TestMolecular Genetic Testing (F8 Gene)Hemophilia B Carrier Detection Test
ComparisonHemophilia A Carrier Detection TestMeasures only Factor VIII clotting activity and does not calculate the vWF ratio. Used for diagnosing Hemophilia A in affected individuals rather than carrier detection.Gold standard for definitive carrier confirmation. Identifies specific mutations in the F8 gene. More expensive but provides conclusive results, especially for borderline biochemical cases.Detects carriers of Hemophilia B (Factor IX deficiency) using Factor IX and related assays. Used when Factor IX deficiency is suspected rather than Factor VIII deficiency.

Frequently Asked Questions

What is the Hemophilia A Carrier Detection Test?
The Hemophilia A Carrier Detection Test is a specialized blood test that determines whether a woman carries the gene for Hemophilia A, an X-linked recessive bleeding disorder. It works by measuring the ratio of Factor VIII clotting activity to von Willebrand Factor (vWF) antigen levels. A ratio below 1.0 is suggestive of carrier status and can identify approximately 95–99% of carriers.
Who should consider getting the Hemophilia A Carrier Detection Test?
Women with a family history of Hemophilia A should consider this test, including sisters, daughters, and mothers of affected males. It is also recommended for women planning pregnancy when there is a known or suspected history of Hemophilia in the family, and for females found to have unexpectedly low Factor VIII levels during routine coagulation screening.
How is the test performed?
The test requires a 3 mL blood sample collected in a Sodium Citrate (Blue Top) tube via venipuncture. The sample is processed in the laboratory using electromechanical clot detection and enzyme immunoassay (EIA) methods to measure Factor VIII activity, vWF antigen concentration, and their ratio.
What sample type is required for this test?
The test requires 3 mL of whole blood collected in a Blue Top (Sodium Citrate) tube. The sample must be mixed thoroughly by gentle inversion immediately after collection and transported to the laboratory within 4 hours. If delayed, platelet-poor plasma (PPP) must be prepared and frozen.
What does a Factor VIII/vWF ratio less than 1.0 indicate?
A Factor VIII/vWF ratio less than 1.0 indicates that Factor VIII clotting activity is disproportionately lower than the vWF antigen level, which is characteristic of Hemophilia A carrier status. This biochemical pattern is seen in 95–99% of confirmed carriers. Confirmatory molecular genetic testing of the F8 gene is recommended for definitive diagnosis.
Can males be tested with the Hemophilia A Carrier Detection Test?
This test is primarily designed for female carrier detection. Males who carry the Hemophilia A gene on their single X chromosome are typically affected by the disorder rather than being silent carriers. In males, a low Factor VIII level with a normal or elevated vWF antigen level would suggest Hemophilia A itself, not carrier status. A standard Factor VIII Activity test is more appropriate for diagnosing males.
How accurate is the Hemophilia A Carrier Detection Test?
The Factor VIII/vWF antigen ratio method is highly effective and identifies approximately 95–99% of Hemophilia A carriers. However, a small percentage of confirmed carriers (1–5%) may have a normal ratio. For definitive confirmation, molecular genetic testing to identify the specific F8 gene mutation is recommended.
Is fasting required before the test?
Yes, overnight fasting (8–12 hours) is preferred before sample collection. Fasting helps ensure stable baseline levels of coagulation factors. Water is permitted during the fasting period. Your doctor may provide specific instructions based on your individual health profile.
What medications should be discontinued before the test?
It is recommended that Heparin be discontinued for 1 day and oral anticoagulants (such as Warfarin) be discontinued for 7 days prior to sample collection, as these medications may interfere with coagulation test results. Any medication discontinuation must be done only with the prior consent and guidance of your treating physician.
How long does it take to get the test results?
Results are typically available the next working day after the sample reaches the laboratory. For samples collected on the 1st and 3rd Monday by 11:00 AM, reports are delivered the following day. Results can be accessed via the online portal, email, or WhatsApp.
Is the Hemophilia A Carrier Detection Test covered by insurance?
Insurance coverage for this test varies by provider and policy. The Hemophilia A Carrier Detection Test may not be covered under all insurance plans. It is advisable to check with your insurance provider, and also inquire about government schemes such as PMJAY, CGHS, ECHS, and ESIC for potential reimbursement or coverage.
What is the cost of the Hemophilia A Carrier Detection Test?
The test is available at a special price through DNA Labs India. Free home sample collection is offered for online bookings across major cities in India including Mumbai, Delhi, Bangalore, Hyderabad, Chennai, Kolkata, Pune, Ahmedabad, and many more. Please check the current pricing on our website or contact us for the latest rates and offers.
Worried about the process? Our certified phlebotomists collect thousands of samples every month across India. The process takes under 5 minutes and is virtually painless. Questions? Message us on WhatsApp — we're here 7 days a week.

Related Tests

Activated Protein C-Resistance (APCR) Test

₹5,200

HLA DNA Typing for Bone Marrow Transplant: 10 Antigens PCR Test

₹24,570

HLA DNA Typing for Bone Marrow Transplant: 6 Antigens Luminex Test

₹17,316

P2RY12 Gene Bleeding disorder, platelet-type 8 NGS Genetic Test

₹20,000

PIEZO1 Gene Dehydrated hereditary stomatocytosis NGS Genetic Test

₹20,000

RPS26 Gene Diamond-Blackfan anemia type 10 NGS Genetic Test

₹20,000
For Hospitals & Clinics

Reference Laboratory Services

We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.

LIMS Integration

Your Data Privacy

Your medical data is protected under Indian law.

✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.

✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.

Book Your Test

Enter your details and we'll connect you within 15 minutes.

🧬

Quick Connect

Enter your mobile number and we’ll connect you with the team.

+91

✅ Connecting you now...

🔒 Your number is used to respond to this request.